Concepts (47)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Splenic Neoplasms | 1 | 2014 | 2 | 0.480 |
Why?
|
| Lymphoma, T-Cell | 1 | 2014 | 4 | 0.480 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 59 | 0.470 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 59 | 0.450 |
Why?
|
| Histiocytosis, Sinus | 1 | 2023 | 1 | 0.220 |
Why?
|
| Lymphadenopathy | 1 | 2023 | 4 | 0.220 |
Why?
|
| HIV Infections | 4 | 2023 | 4946 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2021 | 7 | 0.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 6 | 0.190 |
Why?
|
| Plasmablastic Lymphoma | 1 | 2021 | 9 | 0.190 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2021 | 16 | 0.190 |
Why?
|
| Adult | 5 | 2023 | 5664 | 0.130 |
Why?
|
| Uterine Neoplasms | 1 | 2015 | 4 | 0.130 |
Why?
|
| Vaginal Neoplasms | 1 | 2015 | 3 | 0.130 |
Why?
|
| Lymphoma, B-Cell | 1 | 2015 | 11 | 0.130 |
Why?
|
| Spleen | 1 | 2014 | 9 | 0.120 |
Why?
|
| Bone Marrow | 1 | 2014 | 19 | 0.120 |
Why?
|
| Antigens, CD | 1 | 2014 | 23 | 0.120 |
Why?
|
| Liver | 1 | 2014 | 74 | 0.120 |
Why?
|
| Prognosis | 1 | 2014 | 197 | 0.110 |
Why?
|
| Male | 4 | 2023 | 6489 | 0.110 |
Why?
|
| Young Adult | 2 | 2023 | 2357 | 0.110 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2012 | 5 | 0.100 |
Why?
|
| Humans | 6 | 2023 | 14077 | 0.100 |
Why?
|
| South Africa | 3 | 2023 | 7312 | 0.090 |
Why?
|
| Immunohistochemistry | 2 | 2021 | 26 | 0.080 |
Why?
|
| Female | 4 | 2023 | 8751 | 0.060 |
Why?
|
| Middle Aged | 3 | 2021 | 3425 | 0.060 |
Why?
|
| Bone and Bones | 1 | 2023 | 38 | 0.050 |
Why?
|
| Hospitals | 1 | 2023 | 102 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2021 | 10 | 0.050 |
Why?
|
| Genes, myc | 1 | 2021 | 6 | 0.050 |
Why?
|
| Gene Rearrangement | 1 | 2021 | 15 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2021 | 11 | 0.050 |
Why?
|
| Gene Dosage | 1 | 2021 | 23 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2021 | 95 | 0.050 |
Why?
|
| Infant | 1 | 2023 | 2145 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 15 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 25 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2015 | 767 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 10 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 61 | 0.020 |
Why?
|
| Africa South of the Sahara | 1 | 2012 | 328 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2015 | 1410 | 0.020 |
Why?
|
| Aged | 1 | 2015 | 1650 | 0.020 |
Why?
|
| Anti-Retroviral Agents | 1 | 2012 | 542 | 0.020 |
Why?
|
| Adolescent | 1 | 2012 | 2858 | 0.020 |
Why?
|